ibrexafungerp
Selected indexed studies
- The Antifungal Pipeline: Fosmanogepix, Ibrexafungerp, Olorofim, Opelconazole, and Rezafungin. (Drugs, 2021) [PMID:34626339]
- Ibrexafungerp in the Treatment of Vulvovaginal Candidiasis. (Ann Pharmacother, 2023) [PMID:35502451]
- Ibrexafungerp. (, 2012) [PMID:39899770]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- The Antifungal Pipeline: Fosmanogepix, Ibrexafungerp, Olorofim, Opelconazole, and Rezafungin. (2021) pubmed
- Ibrexafungerp in the Treatment of Vulvovaginal Candidiasis. (2023) pubmed
- Ibrexafungerp. (2012) pubmed
- Ibrexafungerp. (2006) pubmed
- Ibrexafungerp: First Approval. (2021) pubmed
- Ibrexafungerp: A narrative overview. (2024) pubmed
- Ibrexafungerp for the treatment of vulvovaginal candidiasis. (2022) pubmed
- Ibrexafungerp: Mechanism of Action, Clinical, and Translational Science. (2025) pubmed
- Pharmacokinetics and Pharmacodynamics of Ibrexafungerp. (2022) pubmed
- Ibrexafungerp for the Treatment of Vulvovaginal Candidiasis: Design, Development and Place in Therapy. (2023) pubmed